1 results match your criteria: "b St Louis College of Pharmacy[Affiliation]"
Comparative effectiveness of lipid-lowering treatments to reduce cardiovascular disease.
Expert Rev Pharmacoecon Outcomes Res
February 2018
b St Louis College of Pharmacy, Pharmacy Administration , St. Louis , MO , USA.
Introduction: The proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor is a new treatment option for patients with hypercholesterolemia. The objective of this study was to systematically review the cost-effectiveness of lipid-lowering agents.
Areas Covered: Based on Pubmed, Embase, and Cochrane Database of Systematic Reviews, we identified 29 relevant articles.